Education
About Us
Working with TipRanks
Follow Us
KALA BIO (KALA)
NASDAQ:KALA
KALA Stock Chart & Stats
$0.62
-$0.34(-4.42%)
At close: 4:00 PM EST
$0.62
-$0.34(-4.42%)
Day’s Range― - ―
52-Week Range$0.61 - $20.60
Previous CloseN/A
Volume15.45K
Average Volume (3M)1.94M
Market Cap
$6.68M
Enterprise Value$28.99M
Total Cash (Recent Filing)$21.10M
Total Debt (Recent Filing)$29.94M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Mar 26, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding10,729,725
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.11
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap4.34
Enterprise Value/Revenue114.14
Enterprise Value/Gross Profit-3.62K
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$1.50Price Target Upside141.94% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Bears Say
Clinical Trial ResultsThe CHASE trial of KPI-012 did not meet the primary endpoint of complete healing of PCED and failed to achieve statistical significance for key secondary efficacy endpoints.
Strategic DecisionsManagement decided to cease development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform due to the trial results.
Workforce ReductionThe company's workforce is being reduced by approximately 51%, indicating potential financial or strategic challenges.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $0.61 and its highest was $20.60 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $6.68M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is Mar 26, 2026 which is in 94 days.
How were KALA BIO’s earnings last quarter?
KALA BIO released its earnings results on Nov 17, 2025. The company reported -$1.01 earnings per share for the quarter, the consensus estimate of -$1.01 by $0.
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Undervalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate is -0.32.
How many shares outstanding does KALA BIO have?
KALA BIO has 10,729,725 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
KALA BIO reported an EPS of -$1.01 in its last earnings report, expectations of -$1.01. Following the earnings report the stock price went down -1.408%.
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
KALA Stock 12 Month Forecast
Average Price Target
$1.50
▲(141.94% Upside)
Technical Analysis
Ownership Overview
6.88% Insiders
2.13% Mutual Funds
12.95% Other Institutional Investors
75.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---